Categories: HealthcareNews

LivaNova to Announce Second-Quarter 2024 Results

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

LONDON–(BUSINESS WIRE)–#advancedcirculatorysupport–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its second-quarter 2024 results prior to the call.


A live audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 926038. A replay will be available on the LivaNova website for 90 days following the call.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the next Company conference call. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contacts

LivaNova Investor Relations and Media Contacts

+1 281-895-2382

Zachary Glazier
Manager, Investor Relations

InvestorRelations@livanova.com
Deanna Wilke
VP, Corporate Communications

Corporate.Communications@livanova.com

Staff

Recent Posts

Best Skin Tag Remover 2025: Revitag Review & Top Skin Tag Removal Tips

Looking for the best skin tag remover in 2025? Discover how Revitag works, plus expert…

9 hours ago

Best Probiotic for Bloating, Gas, and Constipation: Top Probiotic Supplements for Gut Health to Reduce Bloating, Indigestion & Flatulence (YourBiology)

The best probiotics for bloating and gas include strains like Lactobacillus rhamnosus GG, Lactobacillus acidophilus,…

9 hours ago

Best Vyvanse Alternative Over the Counter for ADHD – Natural Vyvanse Substitute – Noocube

NooCube NooCube London, May 10, 2025 (GLOBE NEWSWIRE) -- Vyvanse is a prescription medication that…

9 hours ago

MEDVi Under Review: Best GLP-1 Semaglutide & Terzepatide Compound Solution for Personalized Weight Loss

A Comprehensive Review of MEDVi’s Personalized GLP-1 Weight Loss Solutions Featuring Affordable Compounded Semaglutide and…

9 hours ago

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology…

9 hours ago

Sumatra Slim Belly Tonic Reviews: 2025 Real User Reviews Analyzed & Verified (Blue Tonic for Weight Loss)

LOS ANGELES, May 10, 2025 (GLOBE NEWSWIRE) -- Losing weight these days can feel more…

1 day ago